Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials

Several randomized clinical trials have suggested the effectiveness of bevacizumab (Bev) in early and advanced breast cancer; however, due to the increased toxicity and lack of a clear long-term survival benefit, there is currently no defined role for Bev in breast cancer in the USA, while it has be...

Descripción completa

Detalles Bibliográficos
Autores principales: Nahleh, Zeina, Botrus, Gehan, Dwivedi, Alok, Jennings, Michael, Nagy, Shaimaa, Tfayli, Arafat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388502/
https://www.ncbi.nlm.nih.gov/pubmed/30847174
http://dx.doi.org/10.3892/mco.2019.1796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388502/
https://www.ncbi.nlm.nih.gov/pubmed/30847174
http://dx.doi.org/10.3892/mco.2019.1796

Ejemplares similares